EGFR and non-small cell lung carcinoma: In a randomized, double-blind phase II trial in EGFR-unselected NSCLC patients, no increased benefit in PFS (HR = 1.09, p = 0.69) or OS (HR = 0.80, p = 0.34) was noted in patients receiving onartuzumab plus erlotinib vs. placebo plus erlotinib.